Skip to main content
Premium Trial:

Request an Annual Quote

SGI, Pittsburgh Supercomputing Center, Sigma-Aldrich, Sunset Molecular Discovery, QuantumBio, NIH, RemedyMD, GulfStream Bioinformatics

Premium
PSC Installs ‘Salk’ SGI Altix for Biomedical Research
 
SGI said this week that the Pittsburgh Supercomputing Center has taken delivery of a new Altix 4700 system, called “Salk” for the inventor of the polio vaccine, that will be devoted to biomedical research.
 
PSC acquired the system with support from the National Center for Research Resources. Financial details of the purchase were not disclosed.
 
Salk includes 144 processors and 288 gigabytes of memory.
 

 
Sigma-Aldrich Partners with Sunset Molecular to Expand Gene Search Tool
 
Sigma-Aldrich said this week that it has partnered with Sunset Molecular Discovery to expand data in Sigma’s gene-based search tool, Your Favorite Gene.
 
Sigma said that the collaboration will provide additional information on the functional relationships between bioactive small molecules and genes, and will allow researchers to quickly and easily identify Sigma products that are associated with their genes of interest.
 
Sunset Molecular hosts the chemistry-biology interaction databases Wombat and Wombat-PK, which contain target and bioactivity data.
 
The new information includes more than 3,900 total interactions between bioactive small molecules and their cognate proteins, Sigma said.
 

 
NIH Awards $865K SBIR to QuantumBio to Develop Molecular Modeling Tools
 
QuantumBio said this week that it has been awarded a Small Business Innovation Research grant worth more than $865,000 from the National Institutes of Health to develop molecular modeling software tools.
 
The two-year Phase II SBIR project will focus on developing quantum mechanics-based methods for studying protein/drug interactions. These methods “will ultimately lead to next generation molecular modeling tools used to aid pharmaceutical companies in developing more potent, less expensive drugs and drug-like compounds,” the company said in a statement.
 
In the first phase of the project, the company developed several novel interaction determination methods, which it validated against a number of enzyme targets. The Phase II project will focus on validating these methods with pharmaceutical industry partners, the company said.
 

 
RemedyMD to Integrate GulfStream Bioinformatics' Disease Models with its Research Software
 
RemedyMD and GulfStream Bioinformatics have agreed to integrate their informatics products for translational research, the companies said this week.
 
Under the terms of the agreement, RemedyMD is incorporating GulfStream's 75 disease models into its Investigate data-management platform and is also integrating GulfStream's biospecimen management system, called BIGR, into the Investigate suite.
 
Gary Kennedy, CEO of RemedyMD, said that the combined platform will offer users “a pre-built registry that is already populated with relevant disease-specific data elements, and … a suite of applications and tools to eliminate their data management burdens.”

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.